FIG. 1A



Treatment A: IR fasted
IR (Cohort 1)
IR (Cohort 2)
IR (Cohort 3)
IR (Cohort 4)
LLOQ
Concentration (nM)
1000
100
10
1
0
4
8
12
16
20
24
Time (h)

FIG. 1B



Treatment B: SR Fasted
Concentration (nM)
1000
100
10
1
0
4
8
12
16
20
24
Time (h)
SR1
SR2
SR3
SR4
LLOQ

FIG. 1C



Treatment C: SR Fed
Concentration (nM)
1000
100
10
1
0
4
8
12
16
20
24
Time (h)
SR1
SR2
SR3
SR4
LLOQ

FIG. 2A



Cohort 3: SR3 Fasted vs. High-Fat Meal
Concentration (nM)
1000
100
10
1
0
4
8
12
16
20
24
Time (h)
Fasted
High-Fat Meal
LLOQ

FIG. 2B



Cohort 5: SR3 Fasted vs. Medium-Fat Meal
Concentration (nM)
1000
100
10
1
0
4
8
12
16
20
24
Time (h)
Fasted
Medium-Fat Meal
LLOQ

FIG. 3



Concentration (nM)
100
10
0
4
8
12
16
20
24
Time (h)
Treatment A: 2x25 mg SR3 Fasted
Treatment B: 2x25 mg SR3 Fed (High-fat Meal)
Treatment C: 1x100 mg SR3 Fasted

FIG. 4(a)



Percent Change from Baseline of HGB
4
2
0
-2
-4
-6
-8
0
20
40
60
80
Day
Placebo
100 mg BID
200 mg BID
300 mg QD
600 mg QD

FIG. 4(b)



Change from Baseline of HGB
2
1
0
-1
-2
-3
0
500
1000
1500
Cavg (nM)
Placebo
100 mg BID
200 mg BID
300 mg QD
600 mg QD

FIG. 5



(a)
≥ 50% Reduction in TSS
Percentage of Patients
60
50
40
30
20
10
0
22.2
34.9
50.0
n=9
n=43
n=10
100 mg BID
200 mg BID
600 mg QD
(b)
Median % Change in TSS
Percentage Change From Baseline at Week 12
0
-20
-40
-60
-80
-100
100 mg BID
200 mg BID
600 mg QD
n=6
n=34
n=8
-28.5
-45.8
-76.8

FIG. 6(a)



100 mg BID
200 mg BID
600 mg QD
Mean (±SEM) Hemoglobin (g/dL)
13
12.5
12
11.5
11
10.5
10
9.5
9
0
2
4
6
8
10
12
Weeks

FIG. 6(b)




100 mg BID
200 mg BID
600 mg QD
Mean Hemoglobin (g/L)
125
120
115
110
105
100
0
10
20
30
40
Time (weeks)

FIG. 6(c)


RUXOLITINIB
PLACEBO
Compound of Formula I
Mean Hemoglobin (g/L)
125
120
115
110
105
100
0
12
24
36
48
TIME (weeks)